Phase II Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Luminespib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 23 Oct 2018 Final results published in the Annals of Oncology
- 18 Oct 2017 Primary endpoint (Overall Response Rate to AUY922) has been met, as per results presented at the 18th World Conference on Lung Cancer.
- 18 Oct 2017 Final results of the study assessing activity of AUY922 ,presented at the 18th World Conference on Lung Cancer.